Logo

ExonHit Issues 8.3M in Bonds for Clinical Development

Feb 02, 2004

NEW YORK, Feb. 2 (GenomeWeb News) - ExonHit Therapeutics has issued €8.3 million ($10.3 million) in convertible bonds to existing shareholders and affiliate companies, the Paris-based company said today.

 

The funding will allow ExonHit to operate into 2006 and to conduct clinical trials. The company focuses on alternative RNA splicing, using a gene profiling technology to identify RNA splicing alternatives on a genome-wide scale.

 

ExonHit plans to develop therapeutics and diagnostics for neurodegenerative diseases and cancer. In 2001, the company raised €30 million in a private financing round.

 

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.